A vast majority of the world’s incurable diseases have a common feature implicit in their pathogenesis: cell death and dysfunction. Cellular demise can be seen as the linchpin that unifies such diverse conditions as neurodegenerative disease, diabetes, autoimmune disease, ischemia, and stroke. Neurodon has recognized the importance of this pathological mechanism and is committed to developing safe and effective molecular therapies targeting this feature. This has enabled the discovery of disease-modifying therapeutic candidates for many of these diseases.
A Recurring Theme
Evading Cellular Decline
There are many reasons why disease-modifying medicines that rely on mitigating cell death have been scarce. Historical efforts have focused on manipulating specific components of the various cell death pathways. Neurodon is taking a distinctly different approach by focusing on systemic cellular health. Moving away from the tried targets has enabled Neurodon to develop innovative therapies that have been validated in many preclinical models of disease.
Encouraging Cellular Health
Neurodon has recognized that it is possible to bypass disease-related cell death pathways by maintaining a cellular environment associated with a normal or healthy state. Rather than focusing on specific death machinery, we have identified aberrant aspects of diseased cells that can be effectively corrected with our novel small molecule modulators. Thus, Neurodon’s candidate molecules prevent cell death pathways from ever being initiated.